Literature DB >> 2994986

Enalapril in essential hypertension.

J Herrera-Acosta, H Pérez-Grovas, M Fernández, J Arriaga.   

Abstract

It is now well recognised that the renin-angiotensin system plays a key role in the control of blood pressure not only through circulating angiotensin II but through its interaction with the autonomic and central nervous systems. Angiotensin-converting enzyme (ACE) inhibitors have proved to be effective in lowering blood pressure in different types of hypertension. This study evaluates the antihypertensive effects of enalapril, a new, potent, long acting ACE inhibitor. 50 patients with uncomplicated essential hypertension were included in 4 groups. Group I was used to compare the effects of enalapril and propranolol on blood pressure, renal function, plasma renin activity, aldosterone excretion and plasma lipids in 24 patients after 23 weeks. Group II was used to evaluate long term effects (48 weeks) of these drugs in 13 patients. Group III included 32 patients that received enalapril as monotherapy for 6 to 12 weeks. Group IV was studied to estimate the antihypertensive effect of low doses of hydrochlorothiazide in 18 patients receiving enalapril. The effect on mean blood pressure was similar with enalapril and propranolol (enalapril 117 versus 103 mm Hg and propranolol 115 versus 104 mm Hg); however, the glomerular filtration rate decreased with propranolol (105 versus 87 ml/min; p less than 0.05) and was unaltered with enalapril (102 versus 98 ml/min). Triglycerides rose with propranolol (179 versus 231 mg/dl; p less than 0.05) and did not change with enalapril (157 versus 121 mg/dl). In the long term, antihypertensive effects were similar and no significant side effects were observed. In 14/32 patients blood pressure became normal with enalapril alone. Low doses of hydrochlorothiazide (12.5 to 25 mg) decreased mean blood pressure by 10mm Hg when added to enalapril. The antihypertensive effect of enalapril was similar to that of propranolol; however, the lowering effect on glomerular filtration rate of propranolol did not occur with enalapril. A slight rise in triglycerides occurred only with propranolol. No significant side effects were observed with either propranolol or enalapril. Used as monotherapy, enalapril normalised blood pressure in 44% of cases. Addition of low doses of hydrochlorothiazide significantly increased the antihypertensive effect of enalapril.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994986     DOI: 10.2165/00003495-198500301-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

1.  Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension.

Authors:  A C Guyton; T G Coleman; A V Cowley; K W Scheel; R D Manning; R A Norman
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

2.  Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension.

Authors:  L Hansson; A J Zweifler; S Julius; S N Hunyor
Journal:  Acta Med Scand       Date:  1974 Jul-Aug

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics.

Authors:  L G Navar; L Rosivall
Journal:  Kidney Int       Date:  1984-06       Impact factor: 10.612

5.  Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Authors:  H Gavras; J Biollaz; B Waeber; H R Brunner; I Gavras; R O Davies
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

6.  Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

Authors:  J Biollaz; H R Brunner; I Gavras; B Waeber; H Gavras
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

7.  Renal hemodynamic changes during long-term antihypertensive therapy.

Authors:  S E Warren; D T O'Connor; I M Cohen; J A Mitas
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

8.  beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects.

Authors:  G Berglund; O Andersson
Journal:  Lancet       Date:  1981-04-04       Impact factor: 79.321

9.  Long-term antihypertensive therapy with captopril.

Authors:  J T Groel; S S Tadros; G R Dreslinski; A C Jenkins
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

10.  Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril.

Authors:  S G Chrysant; R D Brown; D C Kem; J L Brown
Journal:  Clin Pharmacol Ther       Date:  1983-06       Impact factor: 6.875

View more
  4 in total

Review 1.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 2.  Serum lipoproteins during treatment with antihypertensive drugs.

Authors:  P Weidmann; C Ferrier; H Saxenhofer; D E Uehlinger; B N Trost
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 4.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.